Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is projected to release its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Ginkgo Bioworks to post earnings of ($1.24) per share and revenue of $38.9450 million for the quarter. Ginkgo Bioworks has set its FY 2025 guidance at EPS.Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last issued its earnings results on Thursday, August 7th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.44) by $0.34. The company had revenue of $49.60 million during the quarter, compared to analyst estimates of $41.60 million. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Ginkgo Bioworks Trading Down 9.5%

DNA stock opened at $11.57 on Wednesday. The stock’s 50 day simple moving average is $12.71 and its 200 day simple moving average is $10.87. Ginkgo Bioworks has a 12-month low of $5.00 and a 12-month high of $17.58. The firm has a market cap of $685.06 million, a P/E ratio of -1.97 and a beta of 1.53.

Insider Transactions at Ginkgo Bioworks

In other Ginkgo Bioworks news, insider Steven P. Coen sold 5,609 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total value of $84,135.00. Following the completion of the transaction, the insider owned 5,503 shares in the company, valued at approximately $82,545. This represents a 50.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.72% of the stock is owned by insiders.

Institutional Trading of Ginkgo Bioworks

Several large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in shares of Ginkgo Bioworks during the second quarter valued at $29,000. Daiwa Securities Group Inc. bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth about $71,000. Acadian Asset Management LLC acquired a new stake in shares of Ginkgo Bioworks in the 1st quarter worth approximately $120,000. New York State Common Retirement Fund bought a new position in shares of Ginkgo Bioworks in the second quarter valued at approximately $138,000. Finally, Shay Capital LLC boosted its holdings in shares of Ginkgo Bioworks by 6.2% in the second quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock valued at $218,000 after acquiring an additional 1,124 shares in the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, October 8th. BTIG Research increased their price objective on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a research note on Monday, August 25th. Finally, Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday, August 30th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $9.00.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.